Saturday, 14 December 2024
  
Login

Australia's most trusted
source of pharma news

Saturday, 14 December 2024
News

PBAC quietly says 'No' to subsidy

Posted 31 July 2024 PM

Gilead's hepatitis D treatment Hepcludex has finally been approved for use in Australia but the company has been delivered a blow in its reimbursement efforts with both the PBAC and MSAC rejecting its submissions.

The TGA approved Hepcludex, which is delivered via a subcutaneous injection for the treatment of chronic hepatitis delta virus (HDV) infection in adults with compensated liver yesterday (Tuesday) after close to a 15-month review under priority and orphan status.

To see the whole article, please login

Popular

Is 2024 the Year of Burnout?
Albo puts hand up for pharma selfie
Why pharma redundancies hurt
Top specialist in Deep Fake scam
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2024 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home